Core Viewpoint - Shanghai Lin Qingxuan Cosmetics Group Co., Ltd. is set to become the first domestic high-end skincare stock listed on the Hong Kong Stock Exchange, with an IPO planned to raise over HKD 1 billion and a market valuation of HKD 10.862 billion [2] Group 1: IPO Details - Lin Qingxuan will issue 13,966,450 H shares, with 1,396,650 shares available for public sale in Hong Kong and 12,569,800 shares for international sale [2] - The IPO price is set at HKD 77.77 per share, aiming to raise over HKD 1 billion [2] - The company has attracted seven cornerstone investors, collectively subscribing USD 62 million, including Fidelity Fund and GBA Investment [2] Group 2: Product and Market Position - Lin Qingxuan has been a pioneer in the "oil-based skincare" sector for over a decade, offering a comprehensive product range including essence oils, creams, and masks [3] - The flagship product, "Camellia Oil," has sold over 45 million bottles and has been the top-selling facial essence oil in China for 11 consecutive years [5] - The company ranks first among domestic high-end skincare brands in China and is the only domestic brand in the top 15 high-end skincare brands [6] Group 3: Financial Performance - In the first half of 2025, Lin Qingxuan's revenue surged by 98.3% year-on-year to HKD 1.052 billion, with adjusted net profit increasing by 117.4% to HKD 200 million [6] - The company's revenue growth rate significantly outpaces the industry average from 2022 to 2024 [6] Group 4: Sales Network and Strategy - Lin Qingxuan operates 554 stores nationwide, ranking first among domestic and international high-end skincare brands in terms of store count [8] - The company employs an OMO (Online-Merge-Offline) sales model, achieving a 51.2% compound annual growth rate in online revenue from 2022 to 2024, with a 137.2% year-on-year increase in the first half of 2025 [8] - The brand has a strong online presence with approximately 7.9 million followers on Tmall and over 2.7 million on Douyin, achieving top sales rankings during major shopping events [8] Group 5: Future Outlook - Lin Qingxuan is positioned to benefit from the growing demand for anti-aging and tightening skincare products, supported by its strong R&D capabilities and leading products [9]

华资实业公告，公司拟出资1000万元成立全资子公司恒鲁生物，以推进"创新驱动、多元布局，推动产 业升级"发展战略。新设子公司将利用现有技术平台，开发护肤品及轻体代餐产品，有助于拉长产业 链，提升产品价值链。本次投资无需提交股东会审议，资金来源为公司自筹，不会对公司财务及经营状 况产生不利影响。 ...

Group 1 - Lin Qingxuan has officially launched its public offering today, aiming to list on the Hong Kong Stock Exchange by the end of this month, marking a significant step towards entering the capital market [1][5] - The company has attracted several well-known cornerstone investors, including Fidelity, indicating strong interest and recognition from the international capital market for high-end domestic skincare brands [2][7] - The funds raised from this offering will primarily be used for brand value creation, multi-channel sales network development, strengthening production supply chain capabilities, and enhancing technology research and product portfolio expansion [2][7] Group 2 - There are concerns regarding the sustainability of Lin Qingxuan's high-end positioning and business model, particularly regarding its significant investment in sales and marketing compared to relatively limited investment in research and development [3][8] - The company's revenue heavily relies on its signature camellia oil product, raising questions about its ability to diversify and create a balanced product portfolio for future growth [3][8] - Lin Qingxuan's past marketing strategies, including unique promotional methods, have sparked discussions about their alignment with the brand's high-end professional image, highlighting the need for compliance in marketing activities to maintain consumer trust [3][8] Group 3 - The listing of Lin Qingxuan is viewed as an important attempt for domestic brands to break through in the increasingly competitive Chinese high-end skincare market [4][9] - The market's ultimate evaluation of the company will depend not only on how it narrates its high-end domestic brand story but also on its ability to build a sustainable product strength and brand value system [4][9]

公司计划将所得款项净额，约20%用于品牌价值塑造与传播；约20%用于提升全渠道销售网络的深化构 建；约15%用于加强生产及供应链能力；约15%用于技术研发及产品组合开拓；约15%用于内生孵化与 外延并购双轮驱动，打造品牌矩阵；约5%用于运营及讯息基础设施数字化、智能化建设；约10%用于 营运资金及一般公司用途。 12月18日，中国高端护肤品牌林清轩(2657.HK)今日起至下周二(23日)招股，发售1396.65万股H股，香港 公开发售占10%，其余为国际配售。每股招股价77.77港元，集资约10.86亿港元。一手50股，入场费 3927.72港元。该股预期12月30日挂牌买卖。中信证券及华泰国际为联席保荐人。 本文源自：格隆汇 ...

本文源自：金融界AI电报 中国高端护肤品牌林清轩(2657.HK)今日起至下周二(23日)招股，发售1396.65万股H股，香港公开发售占 10%，其余为国际配售。每股招股价77.77港元，集资约10.86亿港元。一手50股，入场费3927.72港元。 该股预期12月30日挂牌买卖。中信证券及华泰国际为联席保荐人。 公司计划将所得款项净额，约20% 用于品牌价值塑造与传播；约20%用于提升全渠道销售网络的深化构建；约15%用于加强生产及供应链 能力；约15%用于技术研发及产品组合开拓；约15%用于内生孵化与外延并购双轮驱动，打造品牌矩 阵；约5%用于运营及讯息基础设施数字化、智能化建设；约10%用于营运资金及一般公司用途。 ...

Core Viewpoint - Shanghai Lin Qingxuan Cosmetics Group Co., Ltd. is set to become the "first domestic high-end skincare stock" in Hong Kong with its IPO, aiming to raise over HKD 1 billion and achieve a market capitalization of HKD 10.862 billion [4][3]. Group 1: IPO Details - Lin Qingxuan plans to issue 13,966,450 H shares, with 1,396,650 shares for public sale in Hong Kong and 12,569,800 shares for international sale, priced at HKD 77.77 per share [4]. - The company has attracted seven cornerstone investors, collectively subscribing for USD 62 million, including Fidelity Fund and GBA [4]. Group 2: Product and Market Position - Lin Qingxuan has established itself as a leader in the anti-wrinkle skincare segment, with a complete product matrix including essence oils, creams, and masks [5]. - The flagship product, "Camellia Oil," has sold over 45 million bottles and has been the top-selling facial essence oil in China for 11 consecutive years [7]. - The brand ranks first among domestic high-end skincare brands and is the only domestic brand in the top 15 high-end skincare brands in China [8]. Group 3: Financial Performance - In the first half of this year, Lin Qingxuan's revenue surged by 98.3% to HKD 1.052 billion, with adjusted net profit increasing by 117.4% to HKD 200 million [9]. - The company's revenue growth rate significantly outpaces the industry average, supported by a robust sales network [9]. Group 4: Sales Network and Strategy - Lin Qingxuan operates 554 stores nationwide, with over 95% located in shopping malls, ranking first among domestic and international high-end skincare brands [11]. - The company employs an OMO (Online-Merge-Offline) sales model, integrating online and offline channels, which has led to a 51.2% compound annual growth rate in online revenue from 2022 to 2024 [12]. Group 5: Future Outlook - Lin Qingxuan plans to expand into Southeast Asian markets, leveraging its advanced anti-wrinkle technology and comprehensive sales model to redefine domestic high-end skincare [13].

Core Viewpoint - The Hong Kong capital market is experiencing a concentrated IPO wave with six companies from various industries launching public offerings, showcasing trends in new economic sectors such as artificial intelligence, biotechnology, and high-end consumer goods [1] Group 1: Companies and Their Offerings - Insilico Medicine is set to launch the largest Biotech IPO in the Hong Kong market for 2025, planning to issue approximately 94.69 million shares at a price of HKD 24.05 per share, leveraging its Pharma.AI platform for over 30 innovative projects in oncology, immunology, fibrosis, and metabolism [2][3] - Five One Vision, recognized as the "first Physical AI stock," aims to sell 23.975 million shares globally, with a price of HKD 30.5 per share, potentially raising up to HKD 841 million if the over-allotment option is exercised [2][3] - XunCe, a leading provider of real-time data infrastructure and analytics solutions in China's asset management sector, plans to issue 22.5 million shares with a price range of HKD 48-55 per share [3] - Meilian Holdings, a major service provider in China's prefabricated steel structure construction market, intends to issue 24.6 million shares at a price range of HKD 7.10-9.16 per share [3] - Woan Robotics, a global provider of home robotic systems, plans to issue 22.2223 million shares at a price range of HKD 63-81 per share [3] - Lin Qingxuan, a representative of high-end domestic skincare products in China, aims to issue 13.9665 million shares at a price of HKD 77.77 per share [3] Group 2: Market Position and Investment - Insilico Medicine has attracted a strong base of cornerstone investors, including Eli Lilly, Tencent, Temasek, Schroders, UBS, and Oak Tree Capital, along with a robust pre-IPO investment lineup featuring notable firms like Warburg Pincus and Sequoia China [2] - Five One Vision has established a comprehensive technological capability in Physical AI, supported by significant investments from leading firms such as Moolec Science and SenseTime, as well as prominent individual investors [3] - XunCe holds an 11.6% market share in China's real-time data infrastructure and analytics market, ranking first in the asset management sector as of 2024 [3] - Meilian Holdings ranks third in the prefabricated steel structure construction market in China with a market share of 3.5% [3] - Woan Robotics targets markets in Japan, Europe, and North America, focusing on advanced robotic systems [3] - Lin Qingxuan's core product, camellia oil essence, has been the top-selling facial essence oil in China for 11 consecutive years since 2014 [3]

Group 1 - The company, Lin Qingxuan, plans to globally offer 13.96645 million H-shares, with 1.39665 million shares available in Hong Kong and 12.5698 million shares for international offering, subject to reallocation and the exercise of the over-allotment option [1] - The offering price is set at HKD 77.77 per share, with a trading unit of 50 shares, and the shares are expected to start trading on the Hong Kong Stock Exchange on December 30, 2025 [1] - Lin Qingxuan is a high-end domestic skincare brand in China, focusing on anti-wrinkle and firming skincare products, and is known for its flagship brand offering high-end skincare solutions based on camellia oil [1] Group 2 - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares at the offering price, totaling approximately USD 62 million (or about HKD 483 million) [2] - The cornerstone investors include Fidelity, Mega Prime Development Limited, LVC, Duckling Fund, SS Capital, and others, with a total of 620.47 million H-shares to be subscribed [2] Group 3 - The company estimates that the net proceeds from the global offering will be approximately HKD 997.1 million, assuming the over-allotment option is not exercised [3] - The proceeds will be allocated as follows: approximately 20% for brand value enhancement and promotion, 20% for expanding the sales network and establishing overseas channels, 15% for strengthening production and supply chain capabilities, 15% for technology R&D and product development, 15% for brand incubation and strategic acquisitions, 5% for digital and intelligent infrastructure, and 10% for working capital and general corporate purposes [3]

Core Viewpoint - Lin Qingxuan, a high-end domestic skincare brand in China, is set to launch an IPO from December 18 to December 23, 2025, offering 13.9665 million shares at a price of HKD 77.77 per share, with a market debut expected on December 30, 2025 [1][2]. Company Overview - Lin Qingxuan focuses on anti-wrinkle and firming skincare products, leveraging camellia oil as a key ingredient, and has established a strong market presence since its inception in 2012 [1][2]. - The company has developed a reputation for its "oil-based skincare" philosophy, with its first camellia oil essence launched in 2014, which has since become a cornerstone of its product line [1][2]. - Lin Qingxuan's camellia oil essence has ranked first in retail sales among all facial essence products in China for 11 consecutive years since 2014 [1]. Industry Insights - The Chinese skincare market has shown steady growth, with the market size increasing from RMB 332.9 billion in 2019 to an estimated RMB 461.9 billion by 2024, reflecting a compound annual growth rate (CAGR) of 6.8% [2]. - The high-end segment of the skincare market has experienced significant growth, rising from RMB 74.9 billion in 2019 to RMB 114.4 billion in 2024 [2]. - In 2024, Lin Qingxuan ranked 13th among all high-end skincare brands in China, holding a 1.4% market share, and is the only domestic brand in the top 15 [2]. - In the anti-wrinkle and firming product category, Lin Qingxuan ranked 10th among high-end brands, with a 2.2% market share, and is the leading domestic brand in this segment [2]. Fundraising and Use of Proceeds - The company has secured cornerstone investment agreements totaling approximately USD 62 million from various investors [3]. - The estimated net proceeds from the global offering are around HKD 997 million, which will be allocated as follows: 20% for brand value creation, 20% for enhancing the sales network, 15% for production and supply chain capabilities, 15% for R&D and product development, 15% for brand matrix expansion through internal incubation and external acquisitions, 5% for digital and intelligent infrastructure, and 10% for working capital and general corporate purposes [3].

Core Viewpoint - Lin Qingxuan is set to launch an IPO from December 18 to December 23, 2025, aiming to issue 13.9665 million shares at a price of HKD 77.77 per share, with a significant portion allocated for international investors [1] Company Overview - Lin Qingxuan is a high-end domestic skincare brand in China, focusing on anti-wrinkle and firming skincare products, known for its camellia oil-based solutions [1] - The company pioneered the "oil-based skincare" concept and launched its first camellia oil essence in 2014, which has since become a leading product in the facial essence market [1] - Lin Qingxuan has accumulated expertise in cell-level anti-wrinkle essence oil over more than a decade, with its camellia essence oil ranking first in retail sales among all facial essence products in China for 11 consecutive years since 2014 [1] Industry Insights - The Chinese skincare market has shown steady growth, with the market size increasing from RMB 332.9 billion in 2019 to RMB 461.9 billion in 2024, reflecting a compound annual growth rate (CAGR) of 6.8% [2] - The high-end segment of the skincare market has experienced significant growth, rising from RMB 74.9 billion in 2019 to RMB 114.4 billion in 2024 [2] - In 2024, Lin Qingxuan ranked 13th among all high-end skincare brands in China, holding a 1.4% market share, and is the only domestic brand in the top 15 [2] - In the anti-wrinkle and firming product segment, Lin Qingxuan ranked 10th among high-end skincare brands in China, with a 2.2% market share, and is the leading domestic brand in this category [2] Fundraising and Use of Proceeds - The company has secured cornerstone investment agreements with several funds, totaling approximately USD 62 million [3] - The estimated net proceeds from the global offering are around HKD 997 million, which will be allocated as follows: 20% for brand value creation, 20% for enhancing sales networks, 15% for production and supply chain capabilities, 15% for R&D and product development, 15% for brand matrix development through internal incubation and external acquisitions, 5% for digital and intelligent infrastructure, and 10% for working capital and general corporate purposes [3]